Tradestie Institutional Equity Comparison Engine
MESO vs BHVN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BHVN Overall Edge
BHVN Captures Institutional Edge (3โ0 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biohaven Ltd. (BHVN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, MESO trades at N/M Forward P/E with -42.6% operating margin (+390.7% YoY revenue) versus BHVN at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, MESO sits in UNCLASSIFIED (37th %ile IV; Dealer Gamma Walls on Pro) against BHVN sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
MESO N/M vs BHVN N/M Fwd P/E
Growth & Margin Winner
BHVN
Op Margin -42.6% vs 0.0% ยท YoY +390.7% vs +0.0%
Momentum & Technical Winner
BHVN
1Y -16.4% vs +72.1% ยท 52W Pos 6% vs 59%
Options & Structure Winner
BHVN
UNCLASSIFIED (37th %ile IV) vs CONSOLIDATION (18th %ile IV)
MESO
NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap
$1.7B
1M Return
-6.1%
1Y Return
-16.42%
Forward P/E
N/M
Unified AI Score
34.6 / 100
SELL
Tech 25.0
Fund 40.0
Flow 50.0
Mom 50.0
BHVN
NYSE
Biohaven Ltd.
Pharmaceutical Preparations
$13.90
+0.62% 1D
Market Cap
$2.1B
1M Return
+28.99%
1Y Return
+72.09%
Forward P/E
N/M
Unified AI Score
40.7 / 100
SELL
Tech 15.0
Fund 42.0
Flow 68.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
MESO -16.42%
BHVN +72.09%
Spread: +88.51 pp (BHVN Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
MESO TTM Op. Margin: -42.6%
BHVN TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MESO vs BHVN. Trailing 12-month operating profitability (MESO -42.6% vs BHVN 0.0%) and valuation multiples (MESO N/M vs BHVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MESO | BHVN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.7B | $2.1B | Larger Scale | BHVN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +390.7% | +0.0% | Higher Growth | MESO |
| Operating Margin (TTM) Profitability | -42.6% | 0.0% | Higher Margin | BHVN |
| Net Profit Margin Profitability | -47.8% | 0.0% | Higher Margin | BHVN |
| Return on Equity (ROE) Capital Efficiency | -9.9% | -799.5% | Higher ROE | MESO |
| 52-Week Range Position Momentum | 6% ($12โ$22) | 59% ($8โ$18) | Stronger Trend | BHVN |
| Beta / 30D Volatility Risk Regime | 1.18ฮฒ ยท 78% Vol | 1.41ฮฒ ยท 111% Vol | Lower Realized Risk | MESO |
| Unified Institutional Score Composite Signal | 34.6 / 100 (SELL) | 40.7 / 100 (SELL) | Higher Composite | BHVN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full MESO vs BHVN Buy Guide
MESO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
37th %ile
IV Regime
Balanced (25thโ60th %ile)
BHVN
CONSOLIDATION
91d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
18th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither MESO nor BHVN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.